Summary
HEDGE-A will address one of the current main challenges of biopharmaceutical production: The scalability of the recombinant adeno-associated virus (rAAV) production process. Big Data approaches like transcriptomic and proteomic analyses will be used together with synthetic biology tools to engineer cell cultures and improve rAAV production. The objectives of HEDGE-A are to design (1) a suitable cell platform to sustain transfection at high cell densities and (2) a scalable upstream bioprocess to improve rAAV biomanufacturing.
Access to gene therapy is currently extremely limited due to the high cost of producing rAAVs, leading to expensive treatments and making it virtually inaccessible for the general population or even for diseases requiring high dosage. The main limitation is the poor scalability of the current rAAV production process. HEDGE-A will delve into the molecular limitations of the cellular platform and provide a solution to reduce costs, increase titers and help rAAV-based gene therapies reach the wider population. A cost-effective production process for rAAVs will have a high impact in EU competitiveness as it will open the market for countless gene and cell therapies that are currently non-viable due to the required titers to reach clinical trials.
HEDGE-A will present the perfect opportunity for the applicant to join a cutting-edge working environment to fulfil his potential in cell engineering and bioprocess development. The host centre, DTU (Copenhagen) is a leading expert in the field and can provide the essential network to undertake a project like HEDGE-A, bridging academic research and its industrial application.
Access to gene therapy is currently extremely limited due to the high cost of producing rAAVs, leading to expensive treatments and making it virtually inaccessible for the general population or even for diseases requiring high dosage. The main limitation is the poor scalability of the current rAAV production process. HEDGE-A will delve into the molecular limitations of the cellular platform and provide a solution to reduce costs, increase titers and help rAAV-based gene therapies reach the wider population. A cost-effective production process for rAAVs will have a high impact in EU competitiveness as it will open the market for countless gene and cell therapies that are currently non-viable due to the required titers to reach clinical trials.
HEDGE-A will present the perfect opportunity for the applicant to join a cutting-edge working environment to fulfil his potential in cell engineering and bioprocess development. The host centre, DTU (Copenhagen) is a leading expert in the field and can provide the essential network to undertake a project like HEDGE-A, bridging academic research and its industrial application.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101105465 |
| Start date: | 01-05-2024 |
| End date: | 30-04-2026 |
| Total budget - Public funding: | - 214 934,00 Euro |
Cordis data
Original description
HEDGE-A will address one of the current main challenges of biopharmaceutical production: The scalability of the recombinant adeno-associated virus (rAAV) production process. Big Data approaches like transcriptomic and proteomic analyses will be used together with synthetic biology tools to engineer cell cultures and improve rAAV production. The objectives of HEDGE-A are to design (1) a suitable cell platform to sustain transfection at high cell densities and (2) a scalable upstream bioprocess to improve rAAV biomanufacturing.Access to gene therapy is currently extremely limited due to the high cost of producing rAAVs, leading to expensive treatments and making it virtually inaccessible for the general population or even for diseases requiring high dosage. The main limitation is the poor scalability of the current rAAV production process. HEDGE-A will delve into the molecular limitations of the cellular platform and provide a solution to reduce costs, increase titers and help rAAV-based gene therapies reach the wider population. A cost-effective production process for rAAVs will have a high impact in EU competitiveness as it will open the market for countless gene and cell therapies that are currently non-viable due to the required titers to reach clinical trials.
HEDGE-A will present the perfect opportunity for the applicant to join a cutting-edge working environment to fulfil his potential in cell engineering and bioprocess development. The host centre, DTU (Copenhagen) is a leading expert in the field and can provide the essential network to undertake a project like HEDGE-A, bridging academic research and its industrial application.
Status
SIGNEDCall topic
HORIZON-MSCA-2022-PF-01-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
